Aq­tu­al rais­es $16M for liq­uid biop­sy test for rheuma­toid arthri­tis based on cell-free DNA plat­form

Aq­tu­al emerged from stealth on Tues­day with $16 mil­lion in Se­ries A funds and plans to use its cell-free DNA plat­form to de­vel­op a blood test for pa­tients with rheuma­toid arthri­tis in the hopes of more quick­ly get­ting to the best treat­ment.

Ac­cord­ing to the Cal­i­for­nia-based pre­ci­sion med­i­cine com­pa­ny, there are more than 20 avail­able drugs in six drug class­es for rheuma­toid arthri­tis — and most pa­tients try two or three drugs be­fore find­ing one that works best.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER